Oncology
Microbiomepost discussed with Lisa Derosa, oncologist at Gustave Roussy Hospital in Paris, about the link between gut dysbiosis and cancer, shedding light on its role in immunotherapy resistance and patient…
The findings suggest that the microbiota processes environmental carcinogens in ways that lead to cancer.
The findings support the idea that the gut microbiota modulates immune responses, suggesting new avenues for cancer treatment.
The balance of specific microbes in the gut can help predict who will respond to immunotherapy drugs.
The findings of a recent study suggest that the combination of anti-PD-1 immunotherapy with a lack of TREM2 generates a gut environment that promotes inflammation, which improves tumor rejection.
The findings of a recent study suggest that Desulfovibrio can drive cancer progression, paving the way for therapeutic approached that targeting the gut microbiota.
The findings uncover a link between vitamin D, the immune system and gut bacteria, and they suggest that vitamin D levels could be important for cancer immunity and the efficacy…
The findings of a recent study highlight the importance of considering age-related immune changes and gut microbiota composition for developing personalized immunotherapy approaches.
A recent study demonstrated causation between microbial DCA metabolism and anti-tumor CD8+ T cell response in colorectal cancer.
The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.
